In a research report published Friday, Cantor analyst Mara Goldstein reiterated an Overweight rating on shares of Array Biopharma Inc (NASDAQ:ARRY) with a …
Array Biopharma Inc (NASDAQ:ARRY) shares were soaring 17% yesterday on back of a second fiscal quarter update that has given investors signs of …
Array Biopharma Inc (NASDAQ:ARRY) investors celebrated Monday’s positive COLUMBUS Phase 3 results for its BRAF-mutant melanoma cancer treating pipeline drug BRAFI encorafenib, an oral small …
Array BioPharma (NASDAQ:ARRY) shares surged 81% yesterday after the firm conveyed promising phase 3 COLUMBUS results for its BRAF-mutant melanoma cancer treating pipeline …
Array Biopharma Inc Leerink’s top analyst Michael Schmidt was out today with a favorable report on shares of Array Biopharma Inc (NASDAQ:ARRY), raising the …
It is a day full of great news for the biotech-verse as Array Biopharma Inc (NASDAQ:ARRY) shares are shooting 54% today on back …
Array Biopharma Inc (NASDAQ:ARRY) and Pierre Fabre today jointly announced top-line results from Part 1 of the Phase 3 COLUMBUS (Combined LGX818 Used …
Atara Biotherapeutics Inc (NASDAQ:ATRA) On Monday December 14, 2015 shares of Atara Biotherapeutics tanked 37% after the company reported that a phase 2 …
Cantor Fitzgerald analyst Mara Goldstein released a research report on Array Biopharma Inc (NASDAQ:ARRY) reiterating a Buy rating on the stock and providing a price target …
In a research report published Monday, Cantor analyst Mara Goldstein maintained a Buy rating on Array Biopharma (NASDAQ:ARRY) with a $13 price target, …
